Clinical Efficacy and Safety of Da Huoluowan in Treatment of Osteonecrosis with Phlegm Stasis Syndrome

GUO Zhong-hua; DU Shuai-gang; ZHANG Zhong-bo; WAN Xiao-guan; DONG Sheng-jun

doi:10.13422/j.cnki.syfjx.20181214

您当前的位置：

首页 >

文章列表页 >

Clinical Efficacy and Safety of Da Huoluowan in Treatment of Osteonecrosis with Phlegm Stasis Syndrome

更新时间：2024-01-04

- Clinical Efficacy and Safety of Da Huoluowan in Treatment of Osteonecrosis with Phlegm Stasis Syndrome
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 24, Issue 13, Pages: 172-177(2018)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20181214
  CLC： R274.9
- Published：2018
- 稿件说明：
移动端阅览
GUO Zhong-hua, DU Shuai-gang, ZHANG Zhong-bo, et al. Clinical Efficacy and Safety of Da Huoluowan in Treatment of Osteonecrosis with Phlegm Stasis Syndrome[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(13): 172-177.
DOI：

GUO Zhong-hua, DU Shuai-gang, ZHANG Zhong-bo, et al. Clinical Efficacy and Safety of Da Huoluowan in Treatment of Osteonecrosis with Phlegm Stasis Syndrome[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(13): 172-177. DOI： 10.13422/j.cnki.syfjx.20181214.

摘要

目的：探讨大活络丸加减治疗早中期股骨头坏死（ONFH）痰瘀阻络证的疗效及安全性。方法：将180例（317髋）患者随机分为中药组、西药组和中西药组，各60例。分别给予大活络丸加减，双氯芬酸钠，大活络丸加减联合双氯芬酸钠治疗，疗程均为6个月，随访6个月。观察各组患者治疗前后髋关节功能评分量表（harris hip joint function scale，Harris），影像学指标量表和中医证候积分；检测血清白细胞介素-1β（interleukin-1β，IL-1β），肿瘤坏死因子-α（tumor necrosis factor-α，TNF-α），超氧化物歧化酶（superoxide dismutase，SOD）和C反应蛋白（C-reactive protein，CRP）的变化；比较各组有效率、随访6个月复发率和安全性指标。结果：研究期间中药组脱落3例，5髋；西药组脱落5例，8髋；中西药组脱落4例，7髋。中西药组总有效率高于中药组和西药组（P<0.05）；中西药组Harris，影像学指标和中医证候积分，血清IL-1β，TNF-α，SOD和CRP含量改善优于中药组和西药组（P<0.05），中药组与西药组比较无明显差异。有效患者随访复发率比较中西药组P<0.05）。安全性比较西药组P<0.05）。结论：大活络丸加减治疗ONFH痰瘀阻络证的疗效与双氯芬酸钠无明显差异，说明其具有有效性，且安全性评价优于双氯芬酸钠；大活络丸加减联合双氯芬酸钠治疗ONFH痰瘀阻络证具有协同增效的作用，且可降低双氯芬酸钠的不良反应。

Abstract

Objective: To explore the clinical efficacy and safety of Da Huoluowan in treatment of early-to-middle stage osteonecrosis of femoral head (ONFH) with phlegm stasis syndrome. Method: A total of 180 (317 hips) eligible patients were randomly divided into the traditional Chinese medicine (TCM) group

western medicine group and TCM combined with western medicine group

60 cases in each group. The TCM group was treated with Da Huoluowan

western medicine group was treated with diclofenac sodium sustained-release tablets

and Da Huoluowan combined with diclofenac sodium sustained-release tablets was adopted in the TCM combined with western medicine group. The treatment course was 6 months

and the patients were followed up for 6 months.The harris hip joint function scale (Harris)

imaging index scale and TCM syndrome scores were applied to estimate the efficacy in the three groups before and after treatment.The changes of serum interleukin-1β (IL-1β)

tumor necrosis factor-α (TNF-α)

superoxide dismutase (SOD) and C-reactive protein (CRP) were detected

and then the effective rate

recurrence in 6 months of follow-up and safety indexes were compared among groups. Result: The 3 cases (5 hips) withdrew from TCM group

5 cases (8 hips) withdrew from western medicine group

and 4 cases (7 hips) withdrew from the TCM combined with western medicine group. The total effective rate in TCM combined with western medicine group was higher than the TCM group and the western medicine group (P<0.05). After treatment

the improvement in Harris scores

serum IL-1β

TNF-α

SOD and CRP levels in the TCM combined with western medicine group was significantly superior to that in TCM group and western medicine group (P<0.05)

but there was no significant difference between TCM group and western medicine group. The recurrence rate in follow-up of effective patients was as follows:western medicine group < TCM group < TCM combined with western medicine group (P<0.05)

and the safety was as follows:western medicine group < TCM combined with western medicine group < TCM group. Conclusion: There was no significant difference in clinical efficacy between Da Huoluowan and diclofenac sodium sustained-release tablets in treatment of ONFH with phlegm stasis syndrome

indicating the effectiveness of Da Huoluowan. In addition

it had a higher safety than diclofenac sodium sustained-release tablets. Da Huoluowan combined with diclofenac sodium sustained-release tablets showed synergistic Effect and could reduce the incidence of adverse reactions of diclofenac sodium sustained-release tablets.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Bushen Huoxue Prescription Regulates PINP and β-CTX in Treatment of Femoral Head Necrosis with Syndrome of Liver and Kidney Deficiency

Effect of Rubiae Radix et Rhizoma Extract on Liver, Spleen Injury and Expression of Foxp3 in Adjuvant-induced Arthritis Rats

Comparison of Pharmacodynamics Between Aquilariae Lignum Resinatum Ultrafine Powder and var. Ultrafine Powder

Related Author

CAO Yuju

ZHANG Zhihui

TONG Wuyue

ZHANG Peigang

WANG Bowen

CUI Pengtao

LI Ying

LIU Zijia

Related Institution

Nanyang Second General Hospital

Zhengzhou Traditional Chinese Medicine Hospital of Orthopedics

College of Orthopedics and Traumatology，Henan University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰